Management - an experienced and inter-disciplinary team


Following a long-standing career with Epigenomics AG (1998–2011), Oliver Schacht, an expert in the diagnostics industry, has been CEO of Curetis since 2011. He was a co-founder and CFO of Epigenomics AG in Berlin and CEO of the US subsidiary Epigenomics Inc. (Seattle, USA). Oliver has extensive experience in developing and implementing commercial strategies and financing measures (including an IPO), as well as in finance, M&A transactions and alliance negotiations. Oliver obtained his Diploma in European Business Administration at the European School of Business in Reutlingen and London in 1994 as well as a master's degree and a PhD at the University of Cambridge (UK). During his time at Mercer Management Consulting (1995–1999), he worked on projects in the fields of M&A, growth strategies and reorganization in the pharmaceutical, biotechnology and other industries.

Johannes Bacher – COO

Johannes Bacher combines almost 20 years of R&D and managerial experience with extensive expertise in the fields of international project management, finance, human resources, legal affairs and the design of organizational structures. Hence, the Curetis co-founder is ideally suited to managing the general business activity of Curetis. Johannes has a degree in electrical engineering and has already worked for several international medical technology companies, including Hewlett Packard, Agilent and Philips Medical Systems.

Dr. Achim Plum – CBO

Achim Plum joined Curetis in 2015. As Chief Business Officer he is overseeing all commercial activities including global marketing and sales, business development and medical affairs. He joined from a senior management position with Siemens where he was responsible for the assessment and development of novel approaches to the in vitro diagnostics market. Prior to Siemens, Achim worked for eight years with the publicly traded German-American molecular diagnostics company Epigenomics AG, most recently as Senior Vice President Business and Strategy. At Epigenomics he built sales and marketing teams and distribution networks in Europe and the U.S., negotiated strategic commercial agreements with leading diagnostics industry players and led the company’s corporate communications and compliance functions. Following undergraduate studies at the University of Bonn (Germany) and the University of East Anglia in Norwich (UK), Achim obtained his PhD in molecular genetics from the University of Bonn in 1999 for developing and studying novel genetic models of human diseases.

Andreas Boos – CTO

Andreas Boos – CTO

With over 25 years of professional experience at Hewlett Packard, Agilent and Philips, Curetis co-founder Andreas Boos boasts a wealth of international experience in developing and implementing solutions for patient monitoring and on-site molecular diagnostics. As a graduate electrical engineer, Andreas Boos has successfully applied his project management skills to lead the development of several innovative and commercially successful medical devices for the global markets. In addition to his extensive knowledge of customer requirements, Andreas brings to Curetis a comprehensive understanding of quality systems, standards and global regulatory approval procedures.

Christopher Bernard – CEO Curetis USA, Inc. & EVP Global Sales

Chris Bernard has joined Curetis as CEO of Curetis USA, Inc. and EVP Global Sales. He has more than 22 years of experience in the diagnostics and biopharmaceutical industry as well as in the translational research, including roles in senior executive management, strategic development, product commercialization, marketing and sales. Prior to joining Curetis, Chris had been the Chief Commercial Officer at Epic Sciences and responsible for the expansion of Epic’s technology. Prior to Epic Sciences, he was Senior Vice President, Sales and Marketing and an officer at Metabolon Inc and Vice President and Officer at Abaxis Inc. At Abaxis he had been responsible for sales and marketing of the point-of-care diagnostics platform Piccolo Xpress®. He began his career at Cytyc Corporation (Hologic Inc.) where he was regional business director responsible for growth in sales and management of a portfolio of diagnostic products, including the ThinPrep® Pap Test and Imager and NovaSure® endometrial ablation. Chris Bernard holds a BA in psychobiology from Hiram College, Ohio, USA where he also sits on the board of the entrepreneurial leadership program.

Heiko Schorr – Director Finance

Heiko Schorr has worked for Curetis as Director Finance since March 2012. He has nearly 20 years of professional experience in various roles with increasing managerial responsibility in the fields of accounting, taxes, finances and controlling. In his career to date, Heiko Schorr has already established and managed teams of employees in large corporations and in medium-sized high-tech companies. He has introduced ERP systems (Navision) as well as budgeting and reporting systems for various locations and international offices. Heiko has extensive specialist expertise thanks to his previous positions as Head of Finance & Controlling at Betec Electronic GmbH and as Intercompany Accountant at Yves Rocher GmbH. Heiko Schorr has a degree (IFRS economist) from Nürtingen University of Applied Sciences, is a certified accountant (Reutlingen Chamber of Commerce) and completed training to become a tax consultant at Stuttgart Chamber of Tax Consultants.

Riwat Lim - Director Commercial Operations EMEA

Riwat Lim is Director of Commercial Operations EMEA of Curetis.
Riwat joined from QIAGEN where he led a Market Development Team across Northern Europe and drove double digit growth for the TB testing portfolio. While there he also developed strategic working partnerships with distributors and private reference laboratories. He started his career in healthcare working for pharmaceutical companies including Pfizer and Procter & Gamble where he gained experience in Sales, Marketing and Management. He initiated and designed national patient screening services and patient support programs, which are now commissioned by government healthcare authorities. He graduated with a Masters in Economics and Business Administration from Nice University in France. Riwat brings to Curetis his 18 years of passion for patient care and expertise in driving commercial success.

Dr. Helmut Hilbert – Head of Business Development

Dr. Helmut Hilbert has been working for Curetis as Head of Business Development since 2013. Prior to this position, he was employed by Qiagen as Associate Director of Corporate Business Development. In addition to seven years of R&D activities, Dr. Helmut Hilbert has more than ten years' experience in business and corporate development, and has an impressive track record in the fields of licensing, mergers & acquisitions, technology transfer and innovation management. At Qiagen, Helmut was responsible for assessing new technologies and evaluating acquisition candidates and investment opportunities. His responsibilities also included contract negotiations, due diligence and the integration of acquired companies and technologies.


Andreas Posch has joined Curetis as Director GEAR &  BioIT in 2017. He joined from Siemens, where he was responsible for BioIT R&D at Siemens Healthcare as well as Software Sensors & Analytics with Siemens Corporate Technology. As designated Principal Key Expert for Bioinformatics & Systems Medicine at Siemens Healthcare, he developed, executed and directed global innovation and R&D projects focusing on next-generation sequencing for diagnostic purposes, biomarker discovery, multi-scale disease modeling, advanced clinical decision support as well as genetic antibiotic resistance testing (GEAR). He has an academic background in bioinformatics and biotechnology and his Ph.D. within the “Applied Bioscience Technology” program at the Vienna University of Technology was recognized by international awards while the industrial relevance of his thesis resulted in several million Euro funding from industry and competitive research grants.

Bernd Bleile, Ass.iur. - General Counsel

Bernd Bleile has joined Curetis as General Counsel in February 2016. He is responsible for all legal affairs within Curetis, including general legal advice, workshops and trainings on legal topics, contract preparation and review, foundation and legal support of subsidiaries, contact for external lawyers, to appear in court etc. Prior to Curetis, he worked in the area of law at “SMARTRAC”, a leading RFID product developing and manufacturing company, and at a former subsidiary of Daimler “MercedesBenz Technologies” in Sindelfingen. He qualified as a lawyer and graduated as Master of Public Management (Dipl. Verwaltungswirt/FHöV - Rentenversicherung) at the University of Tübingen, University of Applied Sciences Ludwigsburg and German Federal Pension Fund Baden-Württemberg. In addition, he qualified as in-house data protection officer at TÜV-Süd.

Dr. Michael Schleichert - Director IVD Development

Dr. Michael Schleichert joined Curetis as Director IVD Development in 2017. Previously, he was responsible for the development of several molecular assays and automation systems in the field of HPV (human papilloma virus) and the lead of several teams in the IVD division at Greiner Bio-One Diagnostics. He has over 10 years experience in molecular diagnostics and IVD product development. Dr. Michael Schleichert obtained a Ph.D. in molecular biology at the University Freiburg and studied biology at the University Bayreuth.

Dr. Gerd Luedke – Director Innovation, Technology & IP

Dr. Gerd Luedke is able to look back on a twenty-year career in the field of assay development for research and for analytical and diagnostic systems. He has experience in heading up international projects in multiple locations. He has been responsible for the design of molecular diagnostic assays and the development of clinical applications. Prior to co-founding Curetis, Gerd had worked as a project manager for microfluidics systems at Agilent Technologies as well as for test development at Philips Medical Systems. Dr. Gerd Luedke obtained a doctorate in lung cancer tumor biology at Zurich University Hospital and studied Technical Biology at the University of Stuttgart.